AKTS compared with EIKN: revenue, margins and what each company keeps, and the suppliers and customers both name

AKTSAktis Oncology, Inc.

Mkt capRevenueRevenue

EIKNEikon Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AKTSAktis Oncology, Inc.

EIKNEikon Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AKTS3 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.0%▲+4.79%×0.28

May 12 '26—▲+7.99%—

Q1 FY26—▲+8.16%—

EIKN1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+6.97%—

= impliedAKTS realized, solidEIKN realized, hatchedOne scale, both sides: full bar = 17%× = |realized| ÷ impliedSource: market data

AKTSAktis Oncology, Inc.

15.87▲+6.88%· post 15.87

Mkt cap$874.8MRevenue$3MQ2 FY26

EIKNEikon Therapeutics, Inc.

5.96▲+2.01%· post 5.96

ClosedNov 6 '26

Mkt cap$319.4MRevenue—

Compare

ClosedNov 6 '26

AKTSAktis Oncology, Inc.

EIKNEikon Therapeutics, Inc.

15.87▲+6.88%post 15.87

Price

5.96▲+2.01%post 5.96

$874.8M

Mkt cap

$319.4M

Q2 FY26$3M

Revenue

—

AKTS15.87▲+6.88%vsEIKN5.96▲+2.01%ClosedNov 6 '26